C15:0 Supplementation in Young Adults at Risk for Metabolic Syndrome

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Metabolic Syndrome

In brief

This study will determine changes in plasma C15:0 levels in young adults with BMI ≥ 25 in response to 12 weeks of daily oral C15:0 supplementation.

Key facts

Study ID

NCT04947176

Run by

Jeffrey B. Schwimmer, MD

People needed

30

Starts

2021-07-06

Expected to finish

2023-12-01

Last updated by the study team

2023-06-05

Who can join

Age: 18 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 through 25 years
• Body Mass Index ≥ 25 Kg/m2

You may not qualify if…

• Reported habitual dietary intake of C15:0 that consistently exceeds 250 mg per day
• Significant alcohol consumption (average consumption >1 drink/day for females, >2 drink/day for males or episodes of binge drinking >5 drinks/day)
• Inability to swallow capsules
• Type 1 or Type 2 Diabetes
• Liver Cirrhosis
• Pregnancy
• Body weight greater than 125 kg at screening
• LDL-cholesterol > 160 mg/dL
• Triglycerides > 500 mg/dL
• Hemoglobin < 10.0 gm/dL
• Current Omega 3 Fatty Acid supplement usage
• Current use of Statin medications
• Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study
• Patients who are currently enrolled in a clinical trial or who received an investigational study drug within 180 days of screening.
• Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator.
• Failure to give informed consent

Where it is running

• UC San Diego — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.